These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 10366112

  • 41. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, Kneer J, van der Auwera P, Stevens RM, Rheumatology Group 791.
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [Abstract] [Full Text] [Related]

  • 42. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I.
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [Abstract] [Full Text] [Related]

  • 43. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
    Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L.
    Scand J Rheumatol; 2006 Nov; 35(1):35-8. PubMed ID: 16467039
    [Abstract] [Full Text] [Related]

  • 44. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 46. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus.
    Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI.
    Arthritis Rheum; 2005 Oct; 52(10):3073-8. PubMed ID: 16200586
    [Abstract] [Full Text] [Related]

  • 47. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, Shim SC, Sheen DH, Seo YI, Kim HA, Baek HJ, Song YW.
    Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
    [Abstract] [Full Text] [Related]

  • 48. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [Abstract] [Full Text] [Related]

  • 49. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J, Sittl R.
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [Abstract] [Full Text] [Related]

  • 50. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
    Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study Group.
    Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
    [Abstract] [Full Text] [Related]

  • 51. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA.
    J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
    [Abstract] [Full Text] [Related]

  • 52. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
    [Abstract] [Full Text] [Related]

  • 53. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA.
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [Abstract] [Full Text] [Related]

  • 54. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [Abstract] [Full Text] [Related]

  • 55. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S.
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [Abstract] [Full Text] [Related]

  • 56. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM, Scleroderma Clinical Trials Consortium.
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [Abstract] [Full Text] [Related]

  • 57. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR, Feldman BM, Pope JE, Tomlinson GA.
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [Abstract] [Full Text] [Related]

  • 58. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.
    Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, Weisman MH, Lee P.
    J Rheumatol; 1994 Jan; 21(1):105-10. PubMed ID: 8151563
    [Abstract] [Full Text] [Related]

  • 59. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study.
    van Rijthoven AW, Dijkmans BA, Thè HS, Meijers KA, Montnor-Beckers ZL, Moolenburgh JD, Boers M, Cats A.
    J Rheumatol; 1991 Jun; 18(6):815-20. PubMed ID: 1895262
    [Abstract] [Full Text] [Related]

  • 60. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.
    Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.